Asia
Pacific Shuanglin Bio-pharmacy Gets Approval for Human Thrombin Clinical Trial
Pacific Shuanglin Bio-pharmacy (SHE:000403) unit Guangdong Shuanglin obtained clinical trial approval from China's drug regulator for human thrombin.The drug is intended as an adjunctive hemostatic for capillary and venule bleeding during surgery when standard techniques fail, according to a Monday filing with the Shenzhen bourse.Shares of the biotechnology company closed 1% lower Monday.
SHE:000403